Effects of metformin on resistin, insulin like growth factor I and inflammatory factor of obese patients with type 2 diabetes

• Main Author: Sen Wang
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2016-01-01
• Series: Journal of Hainan Medical University
• Subjects: Metformin; Type 2 diabetes; Resistin; IGF-I; Department of Endocrinology; Deyang People's Hospital; Deyang 618000; Sichuan; China. Tel: [phone]; E-mail: [e-mail] Funding: Science Research Project of Sichuan Health Department (140412). 1. Introduction; Inflammatory factors
• Online Access: http://www.jhnykdxxb.com/PDF/201602/15.pdf
• ISSN: 1007-1237; 1007-1237

Objective: To explore the effects of metformin on resistin, insulin like growth factor I (IGF-I) and inflammatory factors in patients with obese type 2 diabetes. Methods: A total of 84 patients clinically diagnosed with obese type 2 diabetes were selected as the research objects, and were randomly divided into two groups according to the order of treatment from January 2014 to December 2014. All the patients were treated with diet control and exercise therapy. As for the 42 cases in the control group, they received conventional therapy, while the 42 cases in the observation group was given extra administration of metformin. The fasting venous blood was sampled for the comparison and analysis of the indexes. Results: After treatment, the FPG (6.10±1.26) mmol/L, FINS (8.24±1.56) mU/L, HbAlc (6.20±0.90)%, HOMA-IR (1.81±0.20) and BMI (27.01±2.94) kg/m2 in the observation group were significantly less than before treatment and the control group (P<0.05); after treatment, IL-6 (8.77±1.43) ng/L, TNF- 毩 (27.07±3.37) ng/L and CRP (5.23±0.56) mg/L in the observation group were significantly decreased compared with before treatment and the control group (P<0.05); after treatment, serum insulin (4.18±0.344) ng/mL and IGF-1 (147.87±18.56) μg/L in the observation group declined significantly compared with before treatment and the control group (P<0.05). Conclusion: Metformin can improve glucose metabolism and insulin resistance, reduce body mass index and inhibit the levels of inflammatory cytokines, serum resistin and insulin like growth factor I for the treatment of obese type 2 diabetes, making it of great value in clinical application.